白蛋白结合型紫杉醇单药治疗老年晚期非小细胞肺癌的临床观察

摘要

Objective To investigate the clinical efficacy and adverse effects of nab-paclitaxel monotherapy in elder-ly advanced non-small cell lung cancer (NSCLC). Method Clinical profile of 50 elderly patients with advanced NSCLC who received nab-paclitaxel monotherapy were retrospectively analyzed. All Patients were administered with intravenous injection of nab-paclitaxel at 260 mg/m2 on day l, or on day 1+day 8, with 21 days as a cycle;The clinical efficacy was evaluated after two cycles at least. Result 50 patients were all evaluable. Overall, the objective response rate (ORR) was 22%, the disease control rates (DCR) was 78%. No correlation between the curative effect of nab-paclitaxel and the patho-logic types, prior use of paclitaxel-based medication and treatment lines were observed, while there was no statistically significant difference (P>0.05). Those patients had a median progression-free survival (PFS) of 4.0 months and a median overall survival (OS) of 12.0 months. For adverse reactions, myelosuppression, nausea, vomiting, fatigue, peripheral neu-rotoxicity and impaired hepatic/renal functions were commonly observed, and most of which were grade 1 or 2. Conclu-sion Nab-paclitaxel monotherapy is fairly effective and well tolerated in elderly patients with advanced non-small cell lung cancer.%目的：探讨白蛋白结合型紫杉醇单药治疗老年晚期非小细胞肺癌的耐受性和临床疗效。方法回顾性分析50例接受白蛋白结合型紫杉醇化疗的老年晚期非小细胞肺癌（NSCLC）患者的临床资料，化疗方案为白蛋白结合型紫杉醇260 mg/m2，静脉滴注，第1天或分为第1天和第8天给药；21d为一个治疗周期，至少完成2个周期后评估疗效。结果50例患者均可评估疗效，客观缓解率（ORR）为22%，疾病控制率（DCR）为78%，白蛋白紫杉醇的疗效与患者既往是否使用过紫杉类药物、病理类型及几线治疗等因素无关，差异无统计学意义（P﹥0.05）。中位无进展生存时间（PFS）为4个月，中位总生存时间（OS）为12个月。本研究主要不良反应为骨髓抑制、恶心呕吐、乏力、周围神经毒性及肝肾功能损害，且多为1～2级不良反应，药物耐受性良好。结论白蛋白结合型紫杉醇单药治疗老年晚期非小细胞肺癌疗效佳，耐受性良好。